TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients starting home-based dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-infinity of Plasma Deleobuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Plasma Deleobuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of [14C]-Radioactivity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue score (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue score (VAS) for urgency-frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of positive samples with dengue specific serotype DENV 1, 2, 3 and/or 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Subjects Achieving ≥ 60% Reduction in BSA of EBS Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of donor lymphohematopoietic chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in functional reactivity to emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in glutamate concentrations in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in resting-state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: c-section rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vaginal operative intervention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: prolonged second stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal and perineum tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: labor outcome in premature infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Potentiated Startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear Potentiated Startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sternberg WM Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS-evoked BOLD Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Metabolic Syndrome Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Clinician-diagnosed Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to death through Day 90
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of high-resolution MRI scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cessation of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first event of ischemic stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Ratios of maximum tumor standardized uptake value (SUVmax) normalized to mean SUV (SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MTD of CPI-613
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parameters of echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comprehension of discharge instructions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of BIBF 1120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suprasystemic pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity to investigational cancer drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Peripheral Nerve Injury (PNI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the baseline relative clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Disease Risk Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dendritic cell recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immune parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative colorectal adenoma recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in number of tracheal intubation associated events (TIAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with HCV RNA undetectable or with at least a 2-log drop from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tolerability of Quadrivalent HPV vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Site-Related Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Distance from the tongue to X axis and Y axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of school children trained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete Responses (CR) and Partial Responses (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dermatologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Restless Leg Syndrome (RLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first trigger of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of teriflunomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of interferon beta-1a PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of interferon beta-1a PD markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of moderate acne vulgaris grade II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With VA Mental Health Care Engagement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: systemic pharmacokinetics of mannitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem Identification rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brief Intervention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Referral to specialty treatment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30% Improvement in JIA Core Set (ACR JIA30 Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Oral Prednisone Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipogenic potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroimaging biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mRNA Transcriptome in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CSF concentration of EFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Rating Scale IV (ADHD RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After the First Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After Each Dose During Double-blind Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chest Tube Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell (RBC) Blood Product Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelets Blood Product Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cryoprecipitate (Cryo) Blood Product Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fresh Frozen Plasma (FFP) Blood Product Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Positive Etanercept Anti-Drug Antibody (ADA) Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytotoxic T-cell response to autologous tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Four hour survival
Endpoint domain: Mortality/survival
Primary endpoint: Urine sucrose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCt ss of telmisartan/amlodipine/chlorthalidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ss of telmisartan/amlodipine/chlorthalidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first documented progression or death
Endpoint domain: Mortality/survival
Primary endpoint: CT evaluation of bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEfRT Task Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of major adverse limb events (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: Participant report of not being abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral Inattention Test (BIT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent improvement in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of first episode of postoperative pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: ongoing pregnancy rate (past 2nd trimester)
Endpoint domain: Mortality/survival
Primary endpoint: Change of Sitting Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Observed maximum (peak) plasma 4-aminopyridine (4-AP) concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach Cmax following study treatment administration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Mechanical Issues With Repeat Administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of pancreatic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular profiling of lung cancer specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mortality in 30 days
Endpoint domain: Mortality/survival
Primary endpoint: severe infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cerebro-vascular accidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evoked Brain Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Area Under the Curve (AUC) for Blood Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contingency Naming Test (CNT) Performance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of bone degenerative diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: complications due to incision
Endpoint domain: Adverse events/effects
Primary endpoint: aesthetic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs) and Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Urine alkalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endometritis Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients indicating fluid challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of eradication of ESBL-producing or carbapenem-resistant bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mortality of sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Percentage reduction of the seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leukocyte Type and Quantity in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MS Activity through CSF, Blood, and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Score of the ASIA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall clinical response rate (OCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete pathologic response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food and nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anthropometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin level after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fear of Cancer Recurrence Inventory (FCRI) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score reduce in Taiwan's SNOT-20 nose and sinusitis evaluation form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the WHOQOL-BREF questionnaire, Taiwan version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The amounts of the immunoglobulin E (IgE) level reduced after the assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Eosinophil Cationic Protein (ECP) level reduced after the assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of treatments required to reach disease remission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative occurrence of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Hospital readmission for cardiovascular cause
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fluorescence lifetime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorenal syndrome type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean daily number of inhalations of Ventavis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Exercise Oxygen Consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of AAV-PRO questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: gene therapy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar macrophage viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weeks to Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Patient Health Questionnaire - 9 over 12-months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interference of pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Leakage (Percent of All Base Plates With Leakage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression on The Edinburgh Postnatal Depression Scale from Baseline to Post Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depression on The Edinburgh Postnatal Depression Scale from Baseline to Follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants with Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Distance walked on a six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of further surgery for inadequate lumpectomy margins
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in PEP Knowledge & Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Bystander Practices
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in Sexual Violence Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in affected limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour profiles of serum calcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour profiles of Ca2+ (ionised calcium)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour profiles of PTH (Parathyroid Hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to pass flatus/stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anxiety levels assessed by State Trait of anxiety Y-A form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels assessed by anxiety analogic visual scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of CuATSM in carotid plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anti-insulin antibodies (AIAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Western Ontario and McMaster Universities Arthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric emptying measured as AUC0-300min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with post-traumatic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Migraine Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numbers of patients with walnut allergy
Endpoint domain: Adverse events/effects
Primary endpoint: change of percent atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of stress hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SarsCoV2 viral copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration-curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Clinically Definite Multiple Sclerosis (CDMS)
Endpoint domain: Mortality/survival
Primary endpoint: Time to Confirmed Expanded Disability Status Scale (EDSS) Progression
Endpoint domain: Mortality/survival
Primary endpoint: Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relative bioavailability of tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes